21. ROLE OF HYPERHOMOCYSTEINEMIA IN THE DEVELOPMENT OF ATHEROSCLEROSIS 153, Return to Table of Contents. ROLE OF hyperhomocysteinemia INTHE DEVELOPMENT OF ATHEROSCLEROSIS*. J Zhou, GH Werstuck, L Watson http://www.ccs.ca/society/congress2002/abstracts/abs/a153.htm

Return to Table of Contents ROLE OF HYPERHOMOCYSTEINEMIA IN THE DEVELOPMENT OF ATHEROSCLEROSIS* J Zhou, GH Werstuck, L Watson, GS Hossain, ABL de Koning, YY Shi, SK Sood, RC Austin Henderson Research Centre and Mcmaster University, Hamilton, Ontario *Supported in part by the Heart and Stroke Foundation of Ontario DNC NEXT

22. RESISTANCE ARTERY MECHANICS IN MICE WITH HYPERHOMOCYSTEINEMIA: EFFECTS OF ANGIOT 245, Return to Table of Contents. RESISTANCE ARTERY MECHANICS IN MICEWITH hyperhomocysteinemia EFFECTS OF ANGIOTENSIN II. Mario Fritsch http://www.ccs.ca/society/congress2002/abstracts/abs/a245.htm

Return to Table of Contents RESISTANCE ARTERY MECHANICS IN MICE WITH HYPERHOMOCYSTEINEMIA: EFFECTS OF ANGIOTENSIN II Mario Fritsch Neves, Agostino Virdis, Rima Rozen*, Ernesto L Schiffrin Clinical Research Institute of Montreal, University of Montreal and *Montreal Children’s Hospital Research Institute, McGill University, Montreal, Quebec, Canada Hyperhomocysteinemia (H-Hcy) may be an independent risk factor for atherosclerotic vascular disease. The purpose of this study was to evaluate whether hyperhomocysteinemia may induce direct vascular changes. Wild-type (+/+) and heterozygous (+/-) methylenetetrahydrofolate reductase (Mthfr) knockout mice, a model of mild H-Hcy, were divided in four groups for a 2-week treatment: wild-type with vehicle infusion (+/+ sham), wild-type with angiotensin (Ang) II infusion (400 ng/Kg/min s.c.), Mthfr +/- sham and Mthfr +/- with Ang II. Second-order branches of mesenteric arteries (lumen diameter < 300 mm) were mounted on a pressurized myograph and exposed to intraluminal pressures ranging from 3 to 140 mmHg. Media thickness and lumen diameter were measured at each pressure level to determine wall mechanical properties. In wild-type mice Ang II determined eutrophic remodeling, increasing media-to-lumen (M/L) ratio (7.5 ± 0.3 vs 5.7 ± 0.2 % ,p <0.01) but not media cross-section (8375 ± 703 vs 9527 ± 494, p>0.05). In Mthfr +/- mice Ang II induced hypertrophic remodeling with increased M/L ratio (7.2 ± 0.2 vs 6.3 ± 0.3 %, p

23. Haematologica Website - E-letters hyperhomocysteinemia IN SPANISH PATIENTS MORE INFORMATION Manuel Vargas, InmaculadaSoto, Carmen R. Pinto, Manuel F. Urgelles Servicio de Hematologia http://www.haematologica.it/e-letters/past/vargas.html

Haematologica 1999; 84:E02 prev index next HYPERHOMOCYSTEINEMIA IN SPANISH PATIENTS: MORE INFORMATION Manuel Vargas, Inmaculada Soto, Carmen R. Pinto, Manuel F. Urgelles Servicio de Hematologia, Hospital Central de Asturias, Oviedo, Spain Correspondence: Manuel Vargas, Servicio de Hematologia, Hospital Central de Asturias, Oviedo, Spain We would like to do several considerations. In that article, the authors comment that it is the first report on the prevalence of hyperhomocysteinemia in a Spanish population with venous thromboembolism (VTE), but we want to remind them that our group have published previously data on hyperhomocysteinemia in Spanish patients with VTE. Table 1 Plasmatic homocysteine levels and percentage of hyperhomocysteinemic individuals in patients and controls. Patients Controls p n Hcy (mmol/l) ns* HHcy (%) ns** Hcy: homocysteinemia. HHcy: Hyperhomocysteinemic persons. n.s.: non-significant * t-Student test. ** Pearson's chi-square test. et al.

24. Hyperhomocysteinemia Is Associated With An Increased Risk Of Click here to read hyperhomocysteinemia is associated with an increased risk ofcardiovascular disease, especially in noninsulin-dependent diabetes mellitus http://www.cardiab.com/pubmed/9445267

25. Hyperhomocysteinemia Is A Risk Factor For Coronary Click here to read hyperhomocysteinemia is a risk factor for coronaryarteriosclerosis in Japanese patients with type 2 diabetes. http://www.cardiab.com/pubmed/10097933

26. Hyperhomocysteinemia: Heart-Disease Risk Factor-or New Red Herring? hyperhomocysteinemia HeartDisease Risk Factor-or New Red Herring? Therefore, someresearchers deduced that hyperhomocysteinemia is causally related to CVD. http://www.acsh.org/publications/priorities/1102/hyper.html

News from ACSH Alcohol Diseases Environmental Health ... Sign ACSH Guestbook Volume 11 Number 2 1999 Hyperhomocysteinemia: Heart-Disease Risk Factor-or New Red Herring? by Dr. Ruth Kava Amino acids are commonly regarded as derived primarily from dietary proteins and as building blocks of bodily proteins. Homocysteine does not fit this generality. First, it is not dietarily important for humans, as the body generally synthesizes it amply. Second, the body does not use it to make proteins. Homocysteine is a metabolic intermediary , and vitamin B The theory that homocysteine is related to CVD stems from ob-servations of patients with genetic disorders involving a lack or im-pairment of one of the enzymes that participate in the conversion of homocysteine. Persons with such conditions develop hyperhomocysteinemia Whether moderately high blood concentrations of homocysteine warn of an elevated risk of CVD has not been determined. Likewise undetermined is whether persons with moderately high blood concentrations of homocysteine would derive cardiovascular benefits from increasing intakes of folate, vitamin B , and/or vitamin B . In cases of genetic hyperhomocysteinemia, very high intakes of these vitamins may decrease blood concentrations of homocysteine and decrease CVD risk. This, however, does not entail that decreasing moderately high homocysteine concentrations will decrease CVD risk.

27. Arch Intern Med -- Page Not Found 161;26282629, November 26, 2001, Is hyperhomocysteinemia a Risk Factor or a Consequenceof Coronary Heart Disease?, Marco Cattaneo, MD Paul Knekt, PhD; Antti http://archinte.ama-assn.org/issues/v161n21/ffull/ilt1126-10.html

Select Journal or Resource JAMA Archives of Dermatology Facial Plastic Surgery Family Medicine (1992-2000) General Psychiatry Internal Medicine Neurology Ophthalmology Surgery MSJAMA Science News Updates Meetings Peer Review Congress The page you requested was not found. The JAMA Archives Journals Web site has been redesigned to provide you with improved layout, features, and functionality. The location of the page you requested may have changed. To find the page you requested, click here HOME CURRENT ISSUE PAST ISSUES ... HELP Error 404 - "Not Found"

28. Arch Intern Med -- Page Not Found Metaanalysis of hyperhomocysteinemia as a Risk Factor for VenousThromboembolic Disease Author Information Joel G. Ray, MD, FRCP http://archinte.ama-assn.org/issues/v158n19/abs/ioi71045.html

Select Journal or Resource JAMA Archives of Dermatology Facial Plastic Surgery Family Medicine (1992-2000) General Psychiatry Internal Medicine Neurology Ophthalmology Surgery MSJAMA Science News Updates Meetings Peer Review Congress The page you requested was not found. The JAMA Archives Journals Web site has been redesigned to provide you with improved layout, features, and functionality. The location of the page you requested may have changed. To find the page you requested, click here HOME CURRENT ISSUE PAST ISSUES ... HELP Error 404 - "Not Found"

29. Hyperhomocysteinemia, Vascular Diseases And Thromboses. hyperhomocysteinemia, vascular diseases and thromboses. Marco Cattaneo. Algelo BianchiBonomi Haemophilia and Thrombosis Center, Department of Internal Medicine. http://www.ramld.ru/labmed/lab2/cattengl.htm

Hyperhomocysteinemia, vascular diseases and thromboses Marco Cattaneo Algelo Bianchi Bonomi Haemophilia and Thrombosis Center, Department of Internal Medicine. IRCCS Ospedale Maggiore. University of Milano, Italy High plasma levels homocysteine are the results of the interplay between congenital and environmental factors. Case-control and cross-sectional studies clearly indicated that mild-to-moderate hyperhomocysteinemia is associated with heightened risk of both arterial and venous thrombosis. On the other hand, prospective studies of healthy subjects at the time of their enrollment did not unequivocally show that hyperhomocysteinemia is associated with a high thrombotic risk. Therefore, additional studies are needed to define whether hyperhomocysteinemia is a risk factor for thrombosis. Randomized, placebo-controlled, double-blind trials of the effects of vitamins on the thrombotic risk are urgently needed. Not only will they help in defining whether the relationship between hyperhomocysteinemia and thrombosis is casual, they will also have a potential dramatic impact in the prevention of thromboembolic events. LABSHOP

30. Abbott Diagnostics Division - Medical Conditions - Heart Disease - Homocysteine Insights Enzymology of hyperhomocysteinemia. hyperhomocysteinemiais a manifestation of derangements in homocysteine metabolism. http://www.abbottdiagnostics.com/medical_conditions/heart_disease/insights1/enzy

Cancer Diabetes Drug Abuse Heart Disease ... Thyroid Enzymology of Hyperhomocysteinemia Homocysteine: The New Risk Factor Cardiovascular Risk Stratification Epidemiology of Hyperhomocysteinemia Homocysteine as a risk factor for coronary heart disease, cerebrovascular disease and stroke Enzymology of Hyperhomocysteinemia Potential Mechanisms of Disease Approaches to Management of the Hyperhomocysteinemic Patient Trials and Treatment of Hyperhomocysteinemia References and Additional Reading Hyperhomocysteinemia is a manifestation of derangements in homocysteine metabolism. According to Rima Rozen, PhD, these may result from genetic mutations in enzymes that metabolize homocysteine, nutritional deficiencies of vitamins that serve as cofactors or substrates for the enzymes, or some combination thereof. A complete understanding of the multifactorial nature of hyperhomocysteinemia requires a basic familiarity with homocysteine metabolism. As described by Dr. Rozen, homocysteine is a by-product of dietary protein. It is metabolized in one of two pathways: remethylation or transsulfuration. Click on the image to view a larger version.

31. Abbott Diagnostics Division - Medical Conditions - Heart Disease - Homocysteine Clinical Insights Epidemiology of hyperhomocysteinemia. http://www.abbottdiagnostics.com/medical_conditions/heart_disease/insights1/epid

Cancer Diabetes Drug Abuse Heart Disease ... Thyroid Epidemiology of Hyperhomocysteinemia Homocysteine: The New Risk Factor Cardiovascular Risk Stratification Epidemiology of Hyperhomocysteinemia Homocysteine as a risk factor for coronary heart disease, cerebrovascular disease and stroke Enzymology of Hyperhomocysteinemia Potential Mechanisms of Disease Approaches to Management of the Hyperhomocysteinemic Patient ... References and Additional Reading Levels increase with age; higher in men Click on the image to view a larger version. Top of page Dr. Wilson emphasized that there are several measurement considerations to keep in mind when evaluating homocysteine and other emerging CHD risk factors. These include test standardization, assay variability, correlation with currently accepted risk factors, the possibility of nonlinear effects, the potential for improvement in risk prediction, and the cost of the assay. New biological markers for CHD risk should be assayed by standardized techniques, show little interlaboratory variability, and be performed by laboratories that meet the accreditation standards of either the Centers for Disease Control or the College of American Pathologists. In addition, the marker should have little biological variability. For example, while fibrinogen and other acute-phase reactants are useful markers on an individual basis, they have tremendous intersubject variability.

32. Preventive Health Care, 2000 Update: Screening And Management Of Hyperhomocystei TITLE Preventive health care, 2000 update screening and management of hyperhomocysteinemiafor the prevention of coronary artery disease events. http://www.guideline.gov/FRAMESETS/guideline_fs.asp?guideline=1928&sSearch_strin

33. Arch Neurol -- Page Not Found Arch Neurol. 55;14071408, November 1998, hyperhomocysteinemia A New RiskFactor for Alzheimer Disease?, Ramon Diaz-Arrastia, MD, PhD. http://archneur.ama-assn.org/issues/v55n11/ffull/ned8005.html

Select Journal or Resource JAMA Archives of Dermatology Facial Plastic Surgery Family Medicine (1992-2000) General Psychiatry Internal Medicine Neurology Ophthalmology Surgery MSJAMA Science News Updates Meetings Peer Review Congress The page you requested was not found. The JAMA Archives Journals Web site has been redesigned to provide you with improved layout, features, and functionality. The location of the page you requested may have changed. To find the page you requested, click here HOME CURRENT ISSUE PAST ISSUES ... HELP Error 404 - "Not Found"

34. Annals Of Internal Medicine: Letters and hyperhomocysteinemia Letter on Pages 548549 Print Version (PDF) Letter 1 tothe Editor hyperhomocysteinemia in retinal artery and retinal vein occlusion. http://www.annals.org/issues/v131n7/full/199910050-00033.html

5 October 1999 Volume 131 Number 7 LETTERS Ocular Venous Occlusion and Hyperhomocysteinemia Letter on Pages Letter 1 to the Editor: De Bruijne and colleagues recently reported that 63.6% of 26 patients with venous ocular thrombosis had either fasting hyperhomocysteinemia or elevated post-methionine loading homocysteine concentrations. This association has been previously published , and, although a control group is lacking, this observation suggests a relation between hyperhomocysteinemia and venous ocular occlusion. Whether homocysteine-lowering treatment may prevent this complication remains to be determined. We recently observed a case that may help to address this question. A 30-year-old man had been treated by peritoneal dialysis since January 1995 for end-stage renal disease caused by focal and segmental hyalinosis. At the start of peritoneal dialysis the fasting total homocysteine concentration was 38 mol/L). Starting in February 1996, dialysis adequacy was poor but the patient declined to undergo hemodialysis. In March 1996, his fasting total homocysteine concentration was 123 mol/L. In April 1996, the patient reported acute loss of vision in his left eye. Branch retinal venous thrombosis was diagnosed. Results of coagulation tests were normal, and the patient had neither diabetes mellitus nor hyperlipidemia. From April 1996 to December 1996, regular ophthalmologic controls showed three episodes of branch retinal venous occlusion in both eyes. Transplantation with a cadaveric kidney done in January 1997 was successful. The patient's serum creatinine level was 95

35. Preventive Health Care, 2000 Update: Screening And Management Of Hyperhomocystei Preventive health care, 2000 update screening and management of hyperhomocysteinemiafor the prevention of coronary artery disease events. http://collection.nlc-bnc.ca/100/201/300/cdn_medical_association/cmaj/vol-163/is

Preventive health care, 2000 update: screening and management of hyperhomocysteinemia for the prevention of coronary artery disease events CMAJ See also: Homocysteine: To screen and treat or to wait and see? Contents Abstract Introduction Methods Screening tests for hyperhomocysteinemia ... References Abstract Objective: To establish guidelines for the screening and treatment of hyperhomocysteinemia in the investigation and management of coronary artery disease (CAD). Options: and B ; adherence to the recommended daily allowance of dietary sources of folate and vitamins B and B Outcomes: This article reviews the available evidence on the association between plasma tHcy levels and CAD and the effect of lowering tHcy levels through vitamin supplementation or dietary intake. Evidence: MEDLINE was searched for relevant English-language articles published from January 1966 to June 1999; also reviewed were additional articles identified from the bibliographies. Benefits, harms and costs: Values: The strength of evidence was evaluated using the methods of the Canadian Task Force on Preventive Health Care. Recommendations: Although there is insufficient evidence to recommend the screening or management of hyperhomocysteinemia at present (grade C recommendation), adherence to recommended daily allowance of dietary sources of folate and vitamins B

36. Homocysteine Levodopa Association With Vascular Disease Archives of Neurology, 1/03 - Levodopatherapy, rather than PD, is a cause of hyperhomocysteinemia in patients http://qualitycounts.com/fphomocysteine.html

This site is supported by commissions from my affiliates. If you could, please place orders directly via the links on my site. iHerb.Com Vitamin Shoppe.com Click here for free Fountain of Youth Newsletter ... Anti-aging Physicians Longevity Affiliates Life Extension Buyer's Club iHerb(5% discount code "qc") Vitacost VitaminShoppe ... Health Conditions Homocysteine Related Topics: cholesterol HDL cholesterol inflammation heart disease ... trans fatty acids Popular Supplements to Reduce Homocysteine: folic acid TMG vitamin C omega-3 ... Homocysteine formulas at iHerb - use this link for an additional 5% discount (discount code "qc") plus free shipping on orders over $60 Alternative News: High Homocysteine - Healthwell.com Homocysteine - Life Extension Magazine Alzheimer's Disease and Dementia: Vitamins Can Help Prevent - WebMD, 2/28/03 - "High levels of a substance in the blood called homocysteine tops the list of potentially new risk factors for heart disease stroke , and now dementia . A new study suggests that high homocysteine levels are linked with mental declines associated with Alzheimer's disease in elderly people ... High homocysteine levels can be treated very easily with vitamins, including folate, niacin , and B-12 "

37. Hyperhomocysteinemia And Arterial Aneurysm Translate this page http://link.springer.de/link/service/journals/10016/contents/01/0026/

38. Treatment Of Hyperhomocysteinemia In..., Annals 15 Dec 97 Treatment of hyperhomocysteinemia in Renal Transplant Recipients. BRIEF COMMUNICATIONS.Treatment of hyperhomocysteinemia in Renal Transplant Recipients. http://www.acponline.org/journals/annals/15dec97/hyprhomo.htm

Annals of Internal Medicine Current Issue Past Issues Library for Internists Subscriptions ... Email this page Annals of Internal Medicine BRIEF COMMUNICATIONS Treatment of Hyperhomocysteinemia in Renal Transplant Recipients A Randomized, Placebo-Controlled Trial Annals of Internal Medicine 15 December 1997. 127:1089-1092. Andrew G. Bostom, MD, MS; Reginald Y. Gohh, MD; Andrew J. Beaulieu, MD; Marie R. Nadeau, MS; Anne L. Hume, PharmD; Paul F. Jacques, ScD; Jacob Selhub, PhD; and Irwin H. Rosenberg, MD Background: Stable renal transplant recipients have an excess prevalence of hyperhomocysteinemia, which is a risk factor for arteriosclerosis. Objective: To determine the effect of treatment with 1) vitamin B or 2) folic acid plus vitamin B on fasting and post-methionine-loading plasma total homocysteine levels in renal transplant recipients. Design: Setting: University-affiliated transplantation program. Patients: 29 clinically stable renal transplant recipients. Intervention: Patients were randomly assigned to one of four regimens: placebo ( n = 8); vitamin B

39. 3rd Conference On Hyperhomocysteinemia CRC Home. EMail this resource to a colleague. Congress, Title 3rd Conference onhyperhomocysteinemia. Date April 11, 2003 - April 12, 2003. City Saarbrücken. http://www.docguide.com/crc.nsf/congresses/4C26AFD3F5A22D2D85256C0E002A6E5F

language='en-us'; City Guide Weather Flying Getting Around Dining ... E-Mail this resource to a colleague Congress Title: 3rd Conference on Hyperhomocysteinemia Date: April 11, 2003 - April 12, 2003 City: Saarbrücken Country: Germany Contact: Mr Knapp Phone: Fax: E-Mail: kchjkna@uniklinik-saarland.de Congress Guide Western European Travel Links Weather CNN Weather forecast USA Today weather Current weather Flying One Travel Travelocity Rail Travel Getting Around Mapquest All car rentals worldwide Travel Europe Eurail Dining World guide to vegetarianism Shopping World Valu-Malls Recreation Skiing in Europe Other Information Foreign languages for travelers Travel information (by country) European travel directory Global Phone ... Nowfone Currency Converter Universal currency converter International currency converter ATM Locator Visa Mastercard

40. EXCESS PREVALENCE OF MILD FASTING HYPERHOMOCYSTEINEMIA AMONG RENAL TRANSPLANT VE EXCESS PREVALENCE OF MILD FASTING hyperhomocysteinemia AMONG RENAL TRANSPLANT VERSUSCORONARY ARTERY DISEASE PATIENTS IN THE ERA OF FOLIC ACID FORTIFIED CEREAL http://www.a-s-t.org/abstracts99/642.htm

EXCESS PREVALENCE OF MILD FASTING HYPERHOMOCYSTEINEMIA AMONG RENAL TRANSPLANT VERSUS CORONARY ARTERY DISEASE PATIENTS IN THE ERA OF FOLIC ACID FORTIFIED CEREAL GRAIN FLOUR 1.4 mg/dL. All subjects lived in the Providence, Rhode Island metropolitan area, and were either non-users of any supplements containing folic acid, vitamins B6 or B12, or had refrained from using such supplements for Conclusion: In the era of folic acid fortified flour, mild hyperhomocysteinemia is much more common among stable renal transplant versus coronary artery disease patients. As a result, renal transplant patients are a preferable high-risk target population for controlled trials evaluating the tenable hypothesis that lowering total homocysteine levels will reduce cardiovascular disease outcomes.

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

Page 2     21-40 of 74    Back | 1  | 2  | 3  | 4  | Next 20